Our Services

Precision Oncology

Test that we offer:

  1. CELLSEARCH® Circulating Tumor Cell Test
  2. Prosigna® Breast Cancer Prognostic Signature Assay

The practice of precision medicine involves a systematic approach to the management of diseases which is customized to individual patients, ensuring the greatest likelihood of positive outcomes. Cancer treatment is a major focus of precision medicine initiatives. Simplistically, precision oncology is underpinned by determining the molecular profile of the disease, and then assigning the patient with the most accurate and effective treatments available, rather that the traditionally applied “one-size-fits-all” approach.

1. CELLSEARCH® Circulating Tumor Cell Test (FDA Approved)

Liquid biopsy testing, inclusive of circulating tumour cell testing (CTC) enumeration, is an aspect of precision oncology that allows the monitoring of cancer progression in a non-invasive way, thus minimizing discomfort while maximizing diagnostic accuracy. The affordability and lack of risk allows liquid biopsy testing to be performed at timely intervals thus allowing early detection of cancer progression, providing insights beyond traditional solid biopsies.
Regulatory approval  USA Food and Drug Adminstration(FDA), HSA
Test description 1. The first and only clinically validated, FDA-cleared blood test for enumerating circulating tumor cells (CTCs). CTCs are cancer cells that detach from a primary tumor and travel through the bloodstream or lymphatic system to other parts of the body.
Benefit 1. An early assessment of patient’s prognosis
2. Detection of changes in patient’s prognosis at any time
3. The more accurate assessment of the patient’s prognosis in cases where CTC and imaging are discordant in patients with metastatic breast cancer, or metastatic colon cancer and in cases where CTCs and PSA are discordant in patients with metastatic prostate cancer
Methodology The CELLSEARCH® System
(The first and only clinically validated, FDA-cleared system for identification, isolation, and enumeration of circulating tumor cells (CTCs) from a simple blood test.)
Target Patients with metastatic breast, prostate, or colorectal cancer.
Specimen requirement
  1. CellSave Preservative Tubes must be used for blood collection
  2. Volume of blood required:  10 mL x 2 (Do not exceed more than 10 mL or less than 8mL)
Interpretation of result Favourable vs Unfavourable prognosis
Storage condition Room temperature(25 Degree Celsius)
TAT Up to 5 working days

2. Prosigna® Breast Cancer Prognostic Signature Assay

Prosigna® is a test which looks at activity of 50 genes in your cancer cells, to predict the chances of your cancer returning over the next 10 years. It informs decision about cancer treatment after surgery and the accuracy of Prosigna®to predict cancer recurrence has been proven in independent clinical studies, involving thousands of women. It is also endorsed by independent regulatory organisations and professional oncology organisations worldwide. Post-menopausal women with newly diagnosed, early stage invasive breast cancer treated with endocrine therapy, Hormone receptor positive (ER or PR) or Lymph node-negative or Lymph node-positive should take Prosigna®breast cancer gene signature test.

Please contact us for more information.

Related Topics

The practice of regular health screening may reveal potential health ...

Read more

Phlebotomy service is available during the operating hours at SAM laboratory...

Read more

Frequently ask questions about our services...

Read more
[/mp_span] [/mp_row]